FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2806806868> ?p ?o ?g. }

• W2806806868 endingPage "1064" @default.
• W2806806868 startingPage "1048" @default.
• W2806806868 abstract "Selective patient recruitment can produce discrepancies between clinical trial results and real-world effectiveness.A systematic literature review and meta-analysis were conducted to assess vedolizumab real-world effectiveness and safety in patients with ulcerative colitis (UC) or Crohn's disease (CD). MEDLINE, MEDLINE In-Process, EMBASE, and Cochrane databases were searched for real-world studies of vedolizumab in adult patients with UC/CD reporting clinical response, remission, corticosteroid-free remission, UC/CD-related surgery or hospitalization, mucosal healing, or safety published from May 1, 2014-June 22, 2017. Response and remission rates were combined in random-effects meta-analyses.At treatment week 14, 32% of UC patients [95% confidence interval (CI) 27-39%] and 30% of CD patients (95% CI 25-34%) were in remission; and at month 12, 46% for UC (95% CI 37-56%) and 30% for CD (95% CI 20-42%). For UC, the rates of corticosteroid-free remission were 26% at week 14 (95% CI 20-34%) and 42% at month 12 (95% CI 31-53%); for CD they were 25% at week 14 (95%, CI 20-31%) and 31% at month 12 (95%, CI 20-45%). At month 12, 33-77% of UC and 6-63% of CD patients had mucosal healing. Nine percent of patients reported serious adverse events.Vedolizumab demonstrated real-world effectiveness in patients with moderate-to-severely active UC or CD, with approximately one-half and one-third of patients, respectively, in remission at treatment month 12. These findings are consistent with clinical trial data and support the long-term benefit-risk profile of vedolizumab." @default.
• W2806806868 created "2018-06-13" @default.
• W2806806868 creator A5038005848 @default.
• W2806806868 creator A5039774206 @default.
• W2806806868 creator A5041223408 @default.
• W2806806868 creator A5042884495 @default.
• W2806806868 creator A5045368553 @default.
• W2806806868 creator A5046814722 @default.
• W2806806868 creator A5054479296 @default.
• W2806806868 creator A5059435501 @default.
• W2806806868 creator A5064719712 @default.
• W2806806868 date "2018-06-04" @default.
• W2806806868 modified "2023-10-18" @default.
• W2806806868 title "Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease" @default.
• W2806806868 cites W1147871078 @default.
• W2806806868 cites W1966954525 @default.
• W2806806868 cites W1985161860 @default.
• W2806806868 cites W2009860714 @default.
• W2806806868 cites W2011837830 @default.
• W2806806868 cites W2026437676 @default.
• W2806806868 cites W2034795132 @default.
• W2806806868 cites W203975472 @default.
• W2806806868 cites W2073414271 @default.
• W2806806868 cites W2077531651 @default.
• W2806806868 cites W2081061562 @default.
• W2806806868 cites W2107328434 @default.
• W2806806868 cites W2108515869 @default.
• W2806806868 cites W2109575442 @default.
• W2806806868 cites W2120522488 @default.
• W2806806868 cites W2138687960 @default.
• W2806806868 cites W2144550346 @default.
• W2806806868 cites W2157823046 @default.
• W2806806868 cites W2160619682 @default.
• W2806806868 cites W2162805528 @default.
• W2806806868 cites W2215084273 @default.
• W2806806868 cites W2274605499 @default.
• W2806806868 cites W2288948277 @default.
• W2806806868 cites W2301614008 @default.
• W2806806868 cites W2312756154 @default.
• W2806806868 cites W2320009631 @default.
• W2806806868 cites W2325873684 @default.
• W2806806868 cites W2326348131 @default.
• W2806806868 cites W2326487862 @default.
• W2806806868 cites W2327744141 @default.
• W2806806868 cites W2330470789 @default.
• W2806806868 cites W2338551345 @default.
• W2806806868 cites W2338562204 @default.
• W2806806868 cites W2340101309 @default.
• W2806806868 cites W2340998595 @default.
• W2806806868 cites W2341775125 @default.
• W2806806868 cites W2341848334 @default.
• W2806806868 cites W2414026316 @default.
• W2806806868 cites W2427633307 @default.
• W2806806868 cites W2474412500 @default.
• W2806806868 cites W2498960570 @default.
• W2806806868 cites W2512023138 @default.
• W2806806868 cites W2522960478 @default.
• W2806806868 cites W2523706394 @default.
• W2806806868 cites W2523926044 @default.
• W2806806868 cites W2525314273 @default.
• W2806806868 cites W2529617706 @default.
• W2806806868 cites W2545034339 @default.
• W2806806868 cites W2560112556 @default.
• W2806806868 cites W2560688864 @default.
• W2806806868 cites W2565805514 @default.
• W2806806868 cites W2586131552 @default.
• W2806806868 cites W2586168536 @default.
• W2806806868 cites W2586264251 @default.
• W2806806868 cites W2586374020 @default.
• W2806806868 cites W2586376369 @default.
• W2806806868 cites W2586391645 @default.
• W2806806868 cites W2586399428 @default.
• W2806806868 cites W2586822917 @default.
• W2806806868 cites W2586830390 @default.
• W2806806868 cites W2586862636 @default.
• W2806806868 cites W2586881209 @default.
• W2806806868 cites W2586941398 @default.
• W2806806868 cites W2587018358 @default.
• W2806806868 cites W2587154085 @default.
• W2806806868 cites W2587223250 @default.
• W2806806868 cites W2587225657 @default.
• W2806806868 cites W2587288222 @default.
• W2806806868 cites W2587342941 @default.
• W2806806868 cites W2587348059 @default.
• W2806806868 cites W2587378975 @default.
• W2806806868 cites W2587412299 @default.
• W2806806868 cites W2587496126 @default.
• W2806806868 cites W2587688764 @default.
• W2806806868 cites W2587715580 @default.
• W2806806868 cites W2596217527 @default.
• W2806806868 cites W2602331900 @default.
• W2806806868 cites W2605803661 @default.
• W2806806868 cites W2605832808 @default.
• W2806806868 cites W2606468045 @default.
• W2806806868 cites W2606842768 @default.
• W2806806868 cites W2607414125 @default.
• W2806806868 cites W2612957985 @default.
• W2806806868 cites W2623221337 @default.

• next